PT-141 for Men: What the Research Shows About Bremelanotide and Male Sexual Function

For men dealing with low sexual desire or erectile dysfunction that does not respond fully to standard medications, PT-141 for men has become a growing subject of clinical discussion. Erectile dysfunction and low sexual desire in men are two problems that often get grouped together in conversation, and equally often treated as the same thing when they are not. The most widely prescribed treatments for ED, the PDE5 inhibitor class that includes sildenafil and tadalafil, address the physical mechanics of erection by increasing blood flow to penile tissue in response to arousal. What they do not address is the desire side of the equation, and for a meaningful proportion of men, that is exactly where the breakdown occurs.

This is the gap that has generated clinical interest in bremelanotide, the compound known in research settings as PT-141. It acts through an entirely different pathway than PDE5 inhibitors. Instead of working peripherally on blood flow, it works centrally on melanocortin receptors in the brain to activate the neurological pathways involved in sexual motivation and desire. It is FDA-approved under the brand name Vyleesi for women with hypoactive sexual desire disorder. In men, its use is off-label, and the evidence base, while promising in certain specific contexts, is meaningfully different in scale and quality from the female indication.

This article covers what the research actually shows about PT-141 in men, what the mechanism is and why it matters, where the evidence is genuinely strong and where it is limited, how it compares to conventional ED treatments, and what the honest questions are before any conversation with a licensed provider. For broader context on peptides as a category, the Complete Beginner’s Guide to Peptide Therapy covers the foundations. For the female side of this topic, the companion article PT-141 for Women covers the FDA-approved indication in detail.

How PT-141 for Men Works and Why That Matters

Understanding PT-141’s mechanism requires stepping back from the way most men think about sexual dysfunction treatment. PDE5 inhibitors like sildenafil work downstream in the sexual response cascade. They prevent the breakdown of cyclic GMP in penile smooth muscle, prolonging the vasodilatory effect of nitric oxide, and allowing blood to fill the erectile chambers more effectively. This mechanism depends on sexual arousal already being present to trigger nitric oxide release in the first place. Without desire or arousal, sildenafil does nothing.

PT-141 works upstream, before any of that peripheral physiology comes into play. It is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) that selectively activates melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the hypothalamus and limbic system. MC4R activation in the medial preoptic area triggers dopamine release into the nucleus accumbens and other reward and motivation circuits. This is the neurological seat of sexual desire and motivation in both men and women.

This mechanistic distinction is clinically significant because it determines which men are most likely to benefit from PT-141. PT-141 for men is not a replacement for PDE5 inhibitors in cases of primarily vasculogenic ED. It addresses a different part of the problem, and in men where desire or central arousal initiation is the limiting factor, it targets something that conventional ED medications do not.

The Evidence in Men: What the Research Actually Shows

The honest starting point for discussing the evidence in men is that it is substantially less robust than the evidence supporting the female indication. The RECONNECT program that led to Vyleesi’s FDA approval enrolled 1,247 women in two Phase 3 randomized controlled trials. The male evidence base consists of smaller Phase 2 trials and one notable real-world survey. That gap is clinically meaningful and should be part of any informed conversation about off-label use.

Phase 2 Randomized Controlled Trial in Men with ED

The most rigorous male-specific study enrolled approximately 150 men with ED of varying etiology, randomized to bremelanotide subcutaneous injection versus placebo on an as-needed basis. The primary finding was that 34% of men in the bremelanotide group reported clinically significant improvement in their ability to achieve and maintain an erection sufficient for intercourse, compared to 9% in the placebo group. Approximately 70% of men in the active group showed improvement on the Patient Global Impression of Improvement (PGI-I) scale.

These results are meaningful in context. A treatment-to-placebo difference of 34% versus 9% represents a genuine signal, and the PGI-I findings suggest that subjective improvement was broader than the primary endpoint captured. However, this is Phase 2 data from a single trial, and it was not sufficient for FDA approval. The compound has not yet completed a Phase 3 program in men.

Combination with PDE5 Inhibitors: The Synergy Signal

One of the more clinically interesting findings in the male bremelanotide literature involves combination use with sildenafil. A study examining co-administration of bremelanotide (7.5 mg) with a low dose of sildenafil (25 mg) in men with ED who were inadequate responders to sildenafil alone found that the combination produced a significantly greater erectile response than sildenafil alone. The proposed mechanism is complementary: sildenafil addresses the peripheral vascular pathway while bremelanotide activates the central desire and arousal pathway. The two mechanisms operate independently and their effects appear to add when both pathways are relevant.

Palatin Technologies, the original developer of bremelanotide, launched a Phase 2 open-label study in 2024 specifically examining a co-formulation of bremelanotide and a PDE5 inhibitor in men who are PDE5 non-responders. This 50-patient study was designed to optimize dosing and evaluate the safety and efficacy of the combination approach, with the stated intent of advancing to a Phase 3 trial if results were positive. As of the time of writing, this represents the most active formal research pathway for male bremelanotide use.

Real-World Survey Data

A real-world survey of men who had used PT-141 on at least two occasions found that 80% reported being more satisfied with their sexual experience and its duration. Patient-reported outcomes of this type are subject to significant selection bias and placebo effects and should not be weighted equally with controlled trial data. They are useful for understanding the subjective experience but cannot substitute for rigorous efficacy evidence.

PT-141 vs Conventional ED Treatments

The relationship between PT-141 and conventional ED medications is not one of replacement but of complementarity in specific contexts. Understanding where each approach is appropriate requires understanding what each one does and does not address.

The practical implication of this comparison is that PT-141 is not the first-line intervention for most men presenting with ED. It is most relevant in two specific contexts: men whose primary issue is desire or motivation rather than physical capacity for erection, and men who are inadequate responders to PDE5 inhibitors and for whom adding a central mechanism component may produce incremental benefit. A licensed provider evaluating male sexual dysfunction will identify which of these categories, if any, applies before discussing PT-141 as a potential option.

For men where declining testosterone is contributing to the picture, the relationship between testosterone, libido, and body composition is covered in the articles on Signs of Low Testosterone in Men Over 40 and TRT After 50: Is It Worth It.

Regulatory Status: PT-141 for Men Is Off-Label

The FDA prescribing information for bremelanotide (Vyleesi) states explicitly that the drug is not indicated for the treatment of HSDD in men or for enhancing sexual performance. This is the unambiguous regulatory position as of April 2026: PT-141 for men is not FDA-approved for any male indication.

Off-label prescribing is a common and legal practice in US medicine. A licensed physician can prescribe any approved drug for any purpose they judge to be clinically appropriate based on available evidence, and off-label use accounts for a meaningful proportion of prescriptions across virtually every specialty. The clinical judgment question here is whether the available Phase 2 evidence in men, combined with the mechanistic rationale and the known safety profile from the female Phase 3 program, supports off-label use for a specific patient.

Safety Profile: What Men Using PT-141 Should Know

The safety data for PT-141 in men comes primarily from the Phase 2 male trials and from the larger Phase 3 female program, which used the same compound at the same dose. The profiles are consistent, and the adverse events reported in men mirror those documented in women.

Commonly Reported Side Effects

Nausea is the most frequent adverse event, reported in approximately 40% of patients on the first dose in the female trials. This decreases substantially with continued use. Facial flushing and headache are also commonly reported. Blood pressure can be transiently affected, which is the most clinically significant safety consideration.

Blood Pressure and Cardiovascular Considerations

PT-141 can cause transient changes in blood pressure. The prescribing information specifies that blood pressure should be measured before each injection and that the drug should not be used when blood pressure is already low. Men with established cardiovascular disease, uncontrolled hypertension, or who are on cardiovascular medications should not use PT-141 without a careful provider assessment. The prescribing information also advises waiting at least 12 hours after any cardiovascular drug before administering PT-141.

Men Who Should Not Use PT-141

Which Men Are Most Likely to Benefit from PT-141

The available male data points toward two clinical profiles where PT-141 discussion with a licensed provider is most grounded in evidence.

The first is men with psychogenic or desire-related sexual dysfunction, where the primary issue is the absence of desire or arousal initiation rather than a physical capacity problem. Clinical experience suggests PT-141 may be effective in men with psychogenic or mixed-etiology erectile dysfunction, or in those whose primary issue is low sexual desire rather than vascular insufficiency. This profile typically includes younger men with performance anxiety, men experiencing desire decline not explained by low testosterone, and men whose ED responds inconsistently to PDE5 inhibitors in ways that suggest a motivational component.

The second profile is men who are inadequate responders to PDE5 inhibitors and for whom adding a central mechanism component may be worthwhile. Up to 40% of ED patients do not respond adequately to PDE5 inhibitors, which represents a significant unmet clinical need. The combination evidence, while still Phase 2, is the most scientifically grounded argument for PT-141 in men, and it is the pathway being pursued in formal Phase 3 development.

For both profiles, the evaluation should include baseline lab work covering testosterone, estradiol, prolactin, and metabolic markers to ensure hormonal contributors are identified and addressed. The pre-therapy lab evaluation is covered in the companion article, What Labs Do You Need Before Starting Peptide Therapy. Whether PT-141 is appropriate in the context of a broader hormone protocol, including TRT, is a clinical conversation that this article on combination therapy addresses in more depth.